Drug intelligence / Profile preview

dicitrinone J

Development stage: Preclinical
Modality: Small Molecules

Overview

Dicitrinone J is a rare carbon-bridged citrinin dimer isolated from the starfish-derived symbiotic fungus *Penicillium sp.* GGF 16-1-2. It is one of several novel secondary metabolites identified for their unique chemical structures and biological potential. Dicitrinone J has demonstrated potent antifungal activity against the plant pathogen *Colletotrichum gloeosporioides*. Furthermore, it has been evaluated for cytotoxic activity against human pancreatic cancer cell lines, including BXPC-3 and PANC-1, as part of research into marine-derived natural products for therapeutic applications.

Beyond the preview

Go deeper on dicitrinone J.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dicitrinone J.

Explore the full profile